Benzylpenicillin benzathine 1.2 million I.U powder for suspension for injection (Brancaster Pharma, UK)
Section 19A approved medicine
Benzylpenicillin benzathine 1.2 million I.U powder for suspension for injection (Brancaster Pharma, UK)
Section 19A approval holder
Pro Pharmaceuticals Group Pty Ltd ABN 20 605 457 430
Phone
1300 077 674
Approved until
Status
Current
Medicines in short supply/unavailable
BICILLIN L-A benzathine benzylpenicillin tetrahydrate 1,200,000 Units / 2.3 mL suspension for injection pre-filled syringe with needle - ARTG 147169
Indication(s)
Intramuscular benzathine benzylpenicillin is indicated in the treatment of infections due to penicillin-sensitive micro-organisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.
The following infections will usually respond to adequate dosage of intramuscular benzathine benzylpenicillin:
- Streptococcal infections (Group A - without bacteraemia). Mild-to-moderate infections of the upper respiratory tract (e.g., pharyngitis).
- Venereal infections - Syphilis, yaws, bejel and pinta.
Medical conditions in which benzathine benzylpenicillin therapy is indicated as prophylaxis:
- Rheumatic fever and/or chorea - Prophylaxis with benzathine benzylpenicillin has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.
Images
